We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Profound Medical (PROF) Moves 5.1% Higher: Will This Strength Last?
Read MoreHide Full Article
Profound Medical (PROF - Free Report) shares rallied 5.1% in the last trading session to close at $7.85. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 17.2% loss over the past four weeks.
The sudden surge in share price can be attributed to positive investor expectations from Profound’s lead marketed product, the Tulsa-Pro system, which is approved for the ablation of prostate tissue. In July 2024, the U.S. Centers for Medicare & Medicaid Services proposed a reimbursement rule under the outpatient prospective payment system for three new CPT Category 1 codes related to the TULSA procedure. The final rule is expected in November 2024 and will take effect on January 1, 2025. An early-stage study is currently comparing the TULSA procedure to radical prostatectomy in men with localized prostate cancer. Profound expects to report interim data from this post-market study in the first half of 2025.
This company is expected to post quarterly loss of $0.31 per share in its upcoming report, which represents a year-over-year change of -19.2%. Revenues are expected to be $3.27 million, up 88.8% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Profound Medical, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on PROF going forward to see if this recent jump can turn into more strength down the road.
Profound Medical is part of the Zacks Medical - Drugs industry. USANA Health Sciences (USNA - Free Report) , another stock in the same industry, closed the last trading session 3.6% higher at $37.83. USNA has returned -9.6% in the past month.
For USANA Health, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.49. This represents a change of -17% from what the company reported a year ago. USANA Health currently has a Zacks Rank of #3 (Hold).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Profound Medical (PROF) Moves 5.1% Higher: Will This Strength Last?
Profound Medical (PROF - Free Report) shares rallied 5.1% in the last trading session to close at $7.85. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 17.2% loss over the past four weeks.
The sudden surge in share price can be attributed to positive investor expectations from Profound’s lead marketed product, the Tulsa-Pro system, which is approved for the ablation of prostate tissue. In July 2024, the U.S. Centers for Medicare & Medicaid Services proposed a reimbursement rule under the outpatient prospective payment system for three new CPT Category 1 codes related to the TULSA procedure. The final rule is expected in November 2024 and will take effect on January 1, 2025. An early-stage study is currently comparing the TULSA procedure to radical prostatectomy in men with localized prostate cancer. Profound expects to report interim data from this post-market study in the first half of 2025.
This company is expected to post quarterly loss of $0.31 per share in its upcoming report, which represents a year-over-year change of -19.2%. Revenues are expected to be $3.27 million, up 88.8% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Profound Medical, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on PROF going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Profound Medical is part of the Zacks Medical - Drugs industry. USANA Health Sciences (USNA - Free Report) , another stock in the same industry, closed the last trading session 3.6% higher at $37.83. USNA has returned -9.6% in the past month.
For USANA Health, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.49. This represents a change of -17% from what the company reported a year ago. USANA Health currently has a Zacks Rank of #3 (Hold).